Skip to main content
. 2023 Mar 29;18:256. doi: 10.1186/s13018-023-03698-5

Table 1.

Characteristics of completed versus discontinued trials and published versus unpublished trials (n = 142)

Characteristic Total Trial status Publication status
Discontinued (57) Completed (85) χ2, P Published (71) Unpublished (71) χ2, P
Intervention
Pharmaceutical 83 (58.45) 32 (22.54) 51 (35.92) Pearson χ2 = 0.44, P = .93 46 (32.39) 37 (26.06) Pearson χ2 = 2.89, P = .41
Behavioral/dietary 6 (4.23) 2 (1.41) 4 (2.82) 2 (1.41) 4 (2.82)
Device 30 (21.13) 13 (9.15) 17 (11.97) 12 (8.45) 18 (12.68)
Procedure 23 (16.2) 10 (7.04) 13 (9.15) 11 (7.75) 12 (8.45)
Funding
Hospital/university 73 (51.41) 31 (21.83) 42 (29.58) Pearson χ2 = 6.14, P = .11 34 (23.94) 39 (27.46) Pearson χ2 = 0.91, P = .82
Industry 30 (21.13) 10 (7.04) 20 (14.08) 17 (11.97) 13 (9.15)
Mixed 29 (20.42) 15 (10.56) 14 (9.86) 15 (10.56) 14 (9.86)
Other 10 (7.04) 1 (0.7) 9 (6.34) 5 (3.52) 5 (3.52)
Published
No 71 (50) 45 (78.9) 26 (30.6) Pearson χ2 = 31.92, P < .001 71 (100) 0 (0.0)
Yes 71 (50) 12 (21.1) 59 (69.4) 0 (0.0) 71 (100)
Completed
No 57 (40.14) 57 (100) 0 (0.0) 12 (16.9) 45 (63.4) Pearson χ2 = 31.92 P < .001
Yes 85 (59.86) 0 (0.0) 85 (100) 59 (83.1) 26 (36.6)
Enrollment; Median: 80 (IQR: 37–164)
< 80 66 (46.48) 34 (59.6) 32 (37.6) Pearson χ2 = 6.64, P = .01 24 (33.8) 42 (59.2) Pearson χ2 = 9.17, P = .002
≥ 80 76 (53.52) 23 (40.4) 53 (62.4) 47 (66.2) 29 (40.8)